Novonesis A/S

DB:NZM2 Stock Report

Market Cap: €25.5b

Novonesis Valuation

Is NZM2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NZM2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NZM2 (€53.64) is trading below our estimate of fair value (€58.14)

Significantly Below Fair Value: NZM2 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NZM2?

Key metric: As NZM2 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NZM2. This is calculated by dividing NZM2's market cap by their current earnings.
What is NZM2's PE Ratio?
PE Ratio90.2x
Earnings€282.79m
Market Cap€25.50b

Price to Earnings Ratio vs Peers

How does NZM2's PE Ratio compare to its peers?

The above table shows the PE ratio for NZM2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average27.4x
SY1 Symrise
36.5x13.6%€14.3b
EVK Evonik Industries
34x32.6%€7.8b
WCH Wacker Chemie
27.5x36.4%€3.4b
ACT AlzChem Group
11.7x12.8%€586.2m
NZM2 Novonesis
90.2x30.7%€190.2b

Price-To-Earnings vs Peers: NZM2 is expensive based on its Price-To-Earnings Ratio (90.2x) compared to the peer average (27.4x).

Price to Earnings Ratio vs Industry

How does NZM2's PE Ratio compare vs other companies in the European Chemicals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
NZM2 90.2xIndustry Avg. 17.0xNo. of Companies12PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NZM2 is expensive based on its Price-To-Earnings Ratio (90.2x) compared to the European Chemicals industry average (17x).

Price to Earnings Ratio vs Fair Ratio

What is NZM2's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NZM2 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio90.2x
Fair PE Ratio25.9x

Price-To-Earnings vs Fair Ratio: NZM2 is expensive based on its Price-To-Earnings Ratio (90.2x) compared to the estimated Fair Price-To-Earnings Ratio (25.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NZM2 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€53.64
€65.05
+21.3%
12.0%€80.18€48.81n/a16
Dec ’25€55.08
€64.91
+17.8%
11.7%€78.58€48.81n/a16
Nov ’25€57.54
€65.42
+13.7%
11.1%€75.07€48.26n/a15
Oct ’25€64.80
€65.37
+0.9%
11.0%€75.09€48.27n/a16
Sep ’25€62.36
€62.34
-0.03%
11.1%€72.40€48.26n/a16
Aug ’25€58.08
€61.43
+5.8%
10.6%€72.36€48.24n/a16
Jul ’25€56.56
€60.30
+6.6%
10.7%€72.39€46.92n/a16
Jun ’25€55.12
€58.62
+6.3%
9.1%€67.02€46.91n/a14
May ’25€51.60
€57.75
+11.9%
9.2%€67.02€46.91n/a14
Apr ’25€54.50
€56.28
+3.3%
9.6%€67.04€45.58n/a14
Mar ’25€52.38
€54.78
+4.6%
8.5%€61.71€43.74n/a14
Feb ’25€49.51
€53.32
+7.7%
8.2%€60.38€43.74n/a13
Jan ’25€50.02
€51.86
+3.7%
8.1%€57.68€43.73n/a13
Dec ’24€47.70
€50.51
+5.9%
9.0%€57.69€43.73€55.0813
Nov ’24€42.29
€48.46
+14.6%
11.9%€57.61€36.84€57.5413
Oct ’24€38.07
€50.16
+31.8%
12.6%€61.70€36.88€64.8013
Sep ’24€39.59
€50.08
+26.5%
11.4%€61.71€40.24€62.3614
Aug ’24€44.75
€51.77
+15.7%
11.3%€61.75€40.27€58.0814
Jul ’24€42.03
€52.85
+25.7%
13.4%€69.84€40.29€56.5614
Jun ’24€45.00
€53.21
+18.3%
12.6%€69.81€42.96€55.1214
May ’24€46.83
€53.10
+13.4%
12.2%€68.45€42.95€51.6014
Apr ’24€46.70
€52.04
+11.4%
12.8%€68.47€42.96€54.5014
Mar ’24€45.48
€52.63
+15.7%
13.5%€69.82€42.97€52.3814
Feb ’24€47.36
€52.93
+11.8%
13.8%€69.91€43.02€49.5114
Jan ’24€47.17
€55.88
+18.5%
13.4%€69.89€44.35€50.0215
Dec ’23€55.44
€55.14
-0.5%
15.1%€72.59€44.36€47.7016

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 12:16
End of Day Share Price 2024/12/18 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Novonesis A/S is covered by 40 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael Vitfell-RasmussenABG Sundal Collier
Jyoti PrakashAlphaValue
Carla BänzigerBank Vontobel AG